Clopidogrel Bisulfate Tablets 硫酸氢氯吡格雷片

Effects and efficacy:
Patients with myocardial infarction (from a few days to less than 35 days), ischemic stroke (from 7 days to less than 6 months) or diagnosed peripheral arterial disease. Patients with acute coronary syndrome Non-ST-segment elevation acute coronary syndrome (including unstable angina or non-Q wave myocardial infarction), including patients with stent implantation after percutaneous coronary intervention, combined with aspirin. For patients with ST-segment elevation acute coronary syndrome, combined with aspirin, can be used in thrombolytic therapy. Alternative treatment for patients allergic or intolerant to aspirin.

Dosage and administration:
Adults and the elderly are usually recommended to take 75 mg once a day orally, but 50 mg once a day can be taken orally according to age, weight, and symptoms, with or without food. For patients with acute coronary syndrome, patients with non-ST-segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) should start with a single loading dose of clopidogrel 300 mg, then continue to take 75 mg once a day, and it is recommended to take it for 12 months (while taking aspirin for a long time). ST-segment elevation acute myocardial infarction: should start with a single loading dose of clopidogrel 300 mg, then take 75 mg once a day for at least 4 weeks (with aspirin, with or without thrombolytics). For patients over 75 years old, do not use a clopidogrel loading dose. Patients with recent myocardial infarction (from a few days to less than 35 days), recent ischemic stroke (from 7 days to less than 6 months) or patients with confirmed peripheral arterial disease: The recommended dose is 75 mg per day, once a day. There is no experience in children.

Adverse reactions:
Common adverse reactions Blood system: non-serious bleeding (3.6%-5.1%); Serious adverse reactions Cardiovascular system: coronary stent thrombosis; Skin: fixed drug eruption; Gastrointestinal: colitis, gastrointestinal bleeding (increased bleeding risk when used with aspirin); Blood system: agranulocytosis, aplastic anemia, massive bleeding, pancytopenia (severe), thrombotic thrombocytopenic purpura; Liver: hepatitis, hepatotoxicity, liver failure; Immune system: hypersensitivity reaction; Nervous system: epidural hematoma, intracranial hemorrhage; Eye: intraocular hemorrhage; Others: rebound effect after withdrawal.

Drug contraindications:
Allergic to this product is prohibited and should be used with caution in case of renal impairment